Skip to content

Trial Summary

A Phase IB/III study of Ipatasertib plus Palbociclib and Fulvestrant versus placebo plus Palbociclib and Fulvestrant in hormone receptor positive and HER2 negative locally advanced unresectable or metastatic breast cancer.

Acronym:

IPATunity150

ACTRN/NCT /ethics:

NCT04060862

Scientific title:

A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer

Sponsor / Cooperative group:

Hoffmann-La Roche

Trial & Patient Characteristics

Cancer TypeBreast
Trial TypeTreatment
PhasePhase I, Phase III
Age Range18 years and older
SexBoth
Tumour Stream -
Cancer StageLocally Recurrent or Locally Advanced, Metastatic or Widespread
Anticipated Start Date2019-11-15
Anticipated End Date-

Participating Hospitals

HospitalAshford Cancer Centre Research
Clinical Trial CoordinatorSue Yeend
Emailsyeend@adelaidecancercentre.com.au
Phone08 8292 2240
Principal InvestigatorDr Kerry Cheong
Recruitment StatusNot Yet Recruiting